Destination Ventricular Assist Device: A Single-Centre Experience With a Newly Approved Therapy for Advanced Heart Failure - PubMed
14 hours ago
- #Ventricular assist device
- #Advanced heart failure
- #Destination therapy
- Destination ventricular assist device (VAD) is a newly approved therapy for advanced heart failure in Australia.
- The study analyzed 18 patients who underwent VAD implantation, showing a median survival of 5.9 years post-discharge.
- Significant improvements were observed in symptoms, quality of life, and right-sided heart catheter indices at 6 and 12 months post-implantation.
- The median time to confirm destination therapy (DT) strategy was 621 days, with transplant ineligibility due to biopsychosocial factors.
- DT VAD is a feasible option for transplant-ineligible patients, improving survival and quality of life.